CEMI - Earnings announcements

HAUPPAUGE, N.Y., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. ("Chembio" or the "Company") (NASDAQ:CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended September 30, 2022. Recent Highlights Achieved third quarter 2022 total revenue of $11.2 million including product revenue of $10.8 million, representing product revenue growth of 16% compared to the prior year periodU.S. product revenue of $4.8 million grew 361% compared to the prior year periodAwarded $3.2 million contract from the CDC for development and clinical validation of Dual-Path Platform (DPP) Syphilis Treponemal Nontreponemal (

HAUPPAUGE, N.Y., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (NASDAQ:CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the third quarter of 2022 after the close of trading on Thursday, November 3, 2022. The company's management team will host a corresponding conference call beginning at 4:30 p.m. Eastern Time on November 3, 2022. Investors interested in listening to the conference call may do so by dialing 888-506-0062 from the US or 973-528-0011 from outside the US and providing Entry Code: 600643 or by accessing www.chembio.com/investors/calendar-of-events/. A replay of the call

HAUPPAUGE, N.Y., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. ("Chembio" or the "Company") (NASDAQ:CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended June 30, 2022. Recent Highlights Achieved second quarter 2022 total revenue of $9.2 million including product revenue of $8.9 million, representing growth of 42% and 125%, respectively, compared to the prior year period: U.S. product revenue of $3.4 million, representing growth of 208% compared to the prior year periodAfrica product revenue of $3.1 million, representing growth of 114% compared to the prior year period Completed

HAUPPAUGE, N.Y., July 21, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (NASDAQ:CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the second quarter of 2022 after the close of trading on Thursday, August 4, 2022. The company's management team will host a corresponding conference call beginning at 4:30 p.m. Eastern Time on August 4, 2022. Investors interested in listening to the conference call may do so by dialing 888-506-0062 from the US or 973-528-0011 from outside the US and providing Entry Code: 558147 or by accessing www.chembio.com/investors/calendar-of-events/. A replay of the call will

HAUPPAUGE, N.Y., April 21, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (NASDAQ:CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the first quarter of 2022 after the close of trading on Thursday, May 5, 2022. The company's management team will host a corresponding conference call beginning at 4:30 p.m. Eastern Time on May 5, 2022. Investors interested in listening to the conference call may do so by dialing 888-506-0062 from the US or 973-528-0011 from outside the US and providing Entry Code: 898553 or by accessing www.chembio.com/investors/calendar-of-events/. A replay of the call will be av

HAUPPAUGE, N.Y., March 03, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. ("Chembio" or the "Company") (NASDAQ:CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter and year ended December 31, 2021. Recent Highlights Achieved record quarterly total revenue of $20.6 million and product revenue of $17.4 million in the fourth quarter of 2021, representing growth of 101% and 154%, respectively, compared to the prior year period, including: U.S. product revenue of $3.2 million, representing growth of 268% compared to the prior year periodLatin America product revenue of $12.0 million, representing growth o

HAUPPAUGE, N.Y., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (NASDAQ:CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the fourth quarter and full year 2021 after the close of trading on Thursday, March 3, 2022. The company's management team will host a corresponding conference call beginning at 4:30 p.m. Eastern Time on March 3, 2022. Investors interested in listening to the conference call may do so by dialing 888-506-0062 from the US or 973-528-0011 from outside the US and providing Entry Code: 516973 or by accessing www.chembio.com/investors/calendar-of-events/. A replay of the

HAUPPAUGE, N.Y., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. ("Chembio" or the "Company") (NASDAQ:CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended September 30, 2021. Recent Highlights Achieved third quarter 2021 total revenue of $12.1 million and product revenue of $9.4 million, representing growth of 17% and 12%, respectively, compared to the prior year period. After reflecting the deferred recognition to the third quarter of 2020 of revenue associated with shipments from the second quarter of 2020, total revenues in the third quarter of 2021 increased by $4.5 million, or 59.2%, co

HAUPPAUGE, N.Y., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (NASDAQ:CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the third quarter of 2021 after the close of trading on Thursday, November 4, 2021. The company's management team will host a corresponding conference call beginning at 4:30 p.m. Eastern Time on November 4, 2021. Investors interested in listening to the conference call may do so by dialing 888-506-0062 from the US or 973-528-0011 from outside the US and providing Entry Code: 938540 or by accessing www.chembio.com/investors/calendar-of-events/. A replay of the call w

HAUPPAUGE, N.Y., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. ("Chembio" or the "Company") (NASDAQ:CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended June 30, 2021. Recent Highlights Achieved second quarter 2021 total revenue of $6.5 million and product revenue of $3.9 million, representing growth of 26% and 4%, respectively, compared to the prior year periodInitiated shipments under a $28.3 million purchase order for DPP SARS-CoV-2 Antigen Tests received from Bio-Manguinhos to support the urgent needs of Brazil's Ministry of Health for delivery during 2021Re

HAUPPAUGE, N.Y., July 22, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (NASDAQ:CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the second quarter of 2021 after the close of trading on Thursday, August 5, 2021. The company's management team will host a corresponding conference call beginning at 4:30 p.m. Eastern Time on August 5, 2021. Investors interested in listening to the conference call may do so by dialing 888-506-0062 from the US or 973-528-0011 from outside the US and providing Entry Code: 629053 or by accessing www.chembio.com/investors/calendar-of-events/. A replay of the call will